Nasal IgA After Intramuscular COVID-19 Vaccination Reflected Exposure More Than Priming Schedule
Mucosal immunity sits at the front door of respiratory infection, yet standard COVID-19 vaccination still relies on intramuscular delivery. In this substudy of the Com-COV trial, investigators examined whether two widely used priming schedules could generate local nasal antibody responses, or whether the signal in the upper airway would instead be driven by community exposure to SARS-CoV-2. The answer was not subtle. Across the sampled long-interval cohorts, there was no evidence of de novo nasal IgA induction after one or two intramuscular doses, regardless of vaccine sequence or baseline serostatus.
The practical consequence is straightforward: serum immunity and nasal immunity did not move in lockstep.
Adults aged 50 years or older who were COVID-19 unvaccinated and SARS-CoV-2 infection-naive entered the parent single-blind, randomised, non-inferiority trial across eight UK sites between Feb 11 and Feb 26, 2021. Participants were assigned to homologous or heterologous schedules using ChAdOx1 nCoV-19 and BNT162b2, with dosing at either 28-day or 84-day intervals. This substudy focused on long-interval cohorts and collected nasal lining fluid with nasosorption strips. Anti-spike and anti-nucleocapsid IgG and IgA were measured in serum and nasal samples using electrochemiluminescence immunoassay, then compared through correlation analysis.
Nasal Sampling Showed a Cohort of Older Adults and a Clear Signal of Exposure
Nasal lining fluid was obtained from 101 participants. Mean age was 59.1 years, with a standard deviation of 5.0 years; 49 participants were women and 33 were from non-White ethnicities. Those demographics matter because mucosal immune responses in older adults are not always a simple mirror of systemic vaccination outcomes, and the nasal compartment can be shaped by prior antigen contact in ways that are easy to miss if only serum is sampled.
A key finding emerged in the anti-spike IgA measurements. Significant rises from baseline were seen in the mucosal compartment after ChAd-BNT and BNT-BNT schedules, with geometric mean concentrations of 612.8 AU/mL and 906.4 AU/mL, respectively. Those increases corresponded to fold rises of 2.78 for ChAd-BNT and 3.11 for BNT-BNT. On paper, those numbers could suggest vaccine-driven mucosal priming. The broader pattern argued something different: the nasal anti-spike IgA trajectory did not track the systemic vaccine response, and it aligned far more closely with evidence of mucosal SARS-CoV-2 exposure.
Systemic Antibody Rise Did Not Explain the Nasal IgA Pattern
The disconnect between compartments was central. Nasal anti-spike IgA showed only a weak association with serum anti-spike IgG, with a Pearson coefficient of 0.13 and a p value of 0.013. By contrast, nasal anti-spike IgA strongly correlated with nasal anti-nucleocapsid IgA, with a Pearson coefficient of 0.78 and an extraordinarily small p value of 5 × 10-77. Nucleocapsid reactivity is not a vaccine product of these platforms; it points toward natural viral exposure. In other words, the upper airway signal looked like a fingerprint of intercurrent infection or mucosal encounter rather than a direct consequence of intramuscular immunisation.
No de novo nasal IgA induction was detected after one or two intramuscular doses across schedules, even when baseline serostatus was taken into account. That is clinically important because it separates what vaccines reliably do well from what they do not appear to accomplish in the nasal mucosa. Intramuscular vaccines remain highly effective at driving systemic immunity, and serum IgG likely continues to explain much of the protection against severe disease. Yet the study suggests that local nasal IgA, which has been associated with protection beyond serum IgG, is not reliably generated by these priming schedules alone.
Nasal IgG Followed Serum Immunity More Closely Than IgA Did
The compartmental pattern was not uniform across antibody classes. Nasal IgG appeared to reflect systemic vaccine responses, while SARS-CoV-2 exposure was associated with additional changes in mucosal IgG. That distinction fits the underlying immunobiology. Intramuscular immunisation is efficient at inducing circulating antibodies and memory B-cell responses, but the induction of resident mucosal plasma cells in the upper airway typically requires local antigen encounter or a delivery route that directly engages mucosal tissue.
This helps explain why the study found mucosal anti-spike IgA increases that were more consistent with exposure than vaccination effect. The nasal mucosa sits at a biologic intersection where recent viral contact can rapidly alter antibody profiles, and asymptomatic community transmission can easily blur the interpretation of post-vaccine mucosal assays. A vaccine-only model cannot account for the strength of the association between nasal anti-spike IgA and nasal anti-nucleocapsid IgA.
Why the Nasal Compartment Matters for Future Vaccine Design
Respiratory vaccines are judged not only by whether they prevent hospitalisation, but also by whether they block infection and onward transmission. A systemic vaccine can be excellent at preventing severe outcomes while still leaving the nasal portal of entry relatively unprotected. The findings here reinforce that point without overstating it. Intramuscular vaccination induces robust systemic immunity and remains central to emergency and routine schedules, yet it does not appear to generate de novo local nasal IgA under these conditions.
That leaves a biologically plausible role for mucosally delivered vaccines as a complementary strategy. Such an approach could, in theory, better engage the upper airway and support sterilising immunity at the site where SARS-CoV-2 first establishes itself. The study does not test that strategy directly, but it gives the rationale renewed clinical weight: if nasal IgA is a desired endpoint, a needle into the muscle may not be the optimal route.
The interpretation is also a caution for future vaccine immunology studies. Mucosal antibody measurements can be confounded by unnoticed infection in the surrounding community, especially when asymptomatic exposure is common. Without concurrent markers such as nucleocapsid reactivity, nasal immune readouts may be misread as vaccine effect when they are actually recording recent viral contact.
For now, the message is narrow and actionable. Systemic immunisation remains essential, but the nasal mucosa did not show de novo IgA priming from these intramuscular schedules. Any strategy aimed at reducing acquisition and transmission will likely need to confront the mucosal compartment directly rather than assume serum responses will automatically extend to the nose.